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Impaired functioning of pancreatic  cells is a key hallmark of type 2
diabetes.  cell function is modulated by the actions of different
classes of heterotrimeric G proteins. The functional consequences of
activating specific  cell G protein signaling pathways in vivo are not
well understood at present, primarily due to the fact that  cell G
protein-coupled receptors (GPCRs) are also expressed by many other
tissues. To circumvent these difficulties, we developed a chemical-
genetic approach that allows for the conditional and selective acti-
vation of specific  cell G proteins in intact animals. Specifically, we
created two lines of transgenic mice each of which expressed a
specific designer GPCR in  cells only. Importantly, the two designer
receptors differed in their G protein-coupling properties (Gq/11 versus
Gs). They were unable to bind endogenous ligand(s), but could be
efficiently activated by an otherwise pharmacologically inert com-
pound (clozapine-N-oxide), leading to the conditional activation of
either  cell Gq/11 or Gs G proteins. Here we report the findings that
conditional and selective activation of  cell Gq/11 signaling in vivo
leads to striking increases in both first- and second-phase insulin
release, greatly improved glucose tolerance in obese, insulin-resistant
mice, and elevated  cell mass, associated with pathway-specific
alterations in islet gene expression levels. Selective stimulation of 
cell Gs triggered qualitatively similar in vivo metabolic effects. Thus,
this developed chemical-genetic strategy represents a powerful ap-
proach to study G protein regulation of  cell function in vivo.
beta cells  G protein-coupled receptors  transgenic mice 
type 2 diabetes
Type 2 diabetes has emerged as one of the major threats tohuman health in the 21st century (1). Impaired function of
pancreatic  cells is one of the key hallmarks of type 2 diabetes,
and therapies targeted at improving  cell function are predicted
to offer considerable therapeutic benefit (2).
 Cell function is modulated by the actions of different classes of
heterotrimeric G proteins which are the immediate downstream
targets of a multitude of G protein-coupled receptors (GPCRs).
Like most other cell types, pancreatic  cells are predicted to
express many different GPCRs (3–5). Several lines of evidence
suggest that activation of Gs-coupled receptors expressed by pan-
creatic  cells, including the glucagon-like peptide (GLP-1) recep-
tor, improves  cell function and can increase in  cell mass via
cAMP-dependent mechanisms (5–7). Pancreatic  cells also ex-
press several Gq/11-coupled receptors, including the M3 muscarinic
acetylcholine (ACh) receptor (M3R) and GPR40, which can pro-
mote insulin release in an agonist-dependent fashion [for recent
reviews, see (5, 8)].
Studies with GLP-1 receptor agonists have yielded detailed
information about the beneficial effects of Gs signaling on  cell
function and whole body glucose homeostasis (note that the GLP-1
receptor is enriched in pancreatic  cells) (5–7). In contrast, much
less is known about the in vivo metabolic consequences of  cell
Gq/11 signaling, primarily due to the lack of receptor subtype-
selective agonists and the widespread expression of most Gq/11-
coupled receptors (4). For example, it remains unknown whether
chronic stimulation of  cell Gq/11 signaling can lead to enhanced
 cell mass, as has been reported for the Gs-coupled GLP-1
receptor (5–7). Moreover, studies with M3R (9) and GPR40 (10)
mutant mice have led to conflicting results regarding the metabolic
consequences of chronic activation of  cell Gq/11 signaling.
To better understand the metabolic consequences and the un-
derlying molecular mechanisms of activating specific  cell G
protein signaling pathways in vivo, the availability of an experimen-
tal system in which specific G protein families can be activated in
a  cell-specific and temporally controlled fashion would be highly
desirable. To address this issue, we developed a chemical-genetic
strategy that allows for the conditional and selective activation of
distinct  cell G proteins in intact animals. Specifically, we created
two lines of transgenic mice each of which expressed a specific
designer GPCR (at similar expression levels) in  cells only.
Importantly, the two M3R-based receptors differed in their G
protein-coupling properties (Gq/11 versus Gs). The two designer
receptors could be efficiently activated by clozapine-N-oxide
(CNO), an otherwise pharmacologically inert compound (11, 12),
but not by ACh, the endogenous M3R ligand. As a result, CNO
treatment of the transgenic mice led to the activation of  cell Gq/11
or Gs signaling pathways in vivo, in a conditional and  cell-selective
fashion.
Our findings demonstrate that this chemical-genetic approach
represents a powerful tool to study the functional roles of distinct
G protein pathways in regulating  cell function in vivo.
Results
Generation of CNO-Sensitive Designer GPCRs with Distinct G Protein-
Coupling Properties. The rat M3R was subjected to distinct muta-
tional modifications to obtain mutant receptors that no longer
respond to the endogenous ligand, ACh, but can be activated by
CNO, a pharmacologically inert metabolite of the antipsychotic
drug, clozapine. We generated two M3R-based mutant receptors,
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referred to as R-q and R-s (Fig. 1), which selectively coupled to G
proteins of the Gq/11 family and to Gs, respectively (see below).
Ligand Binding and G Protein-Coupling Properties of R-q and R-s. We
initially characterized the ligand binding and functional properties
of R-q and R-s in transiently transfected COS-7 cells (SI Appendix,
Table S1 and Fig. S1). Importantly, [3H]-N-methylscopolamine
([3H]NMS) competition binding studies demonstrated that R-q and
R-s lost the ability to bind the endogenous M3R agonist, ACh, but
displayed significantly higher affinity for CNO (17- and 102-fold,
respectively) than for the wild-type (WT) mouse M3R (mM3R) (SI
Appendix, Table S1).
Functional studies showed that CNO treatment of R-q-
expressing cells led to a pronounced increase in intracellular inositol
phosphate (IP) levels (CNO EC50 value: 16.7  5.3 nM; n  3),
consistent with the known preference of R-q for Gq/11 (11). On the
other hand, CNO was essentially inactive at the WT mM3R (SI
Appendix, Fig. S1A). We obtained very similar results when we
studied CNO-induced increases in intracellular calcium levels (SI
Appendix, Fig. S2), another response mediated by activated Gq/11.
CNO-mediated activation of R-q did not lead to any significant
changes in intracellular cAMP levels (SI Appendix, Fig. S1E),
indicating that R-q neither activates nor inhibits Gs. In contrast,
CNO treatment of R-s-expressing cells had virtually no effect on
intracellular IP production (SI Appendix, Fig. S1B) or calcium
accumulation (SI Appendix, Fig. S2), but led to a potent and robust
increase in intracellular cAMP levels (CNO EC50 value: 7.4  1.6
nM; n  3) (SI Appendix, Fig. S1F). Addition of CNO to cells
expressing the WT mM3R had no effect on intracellular cAMP
levels (SI Appendix, Fig. S1E). These observations indicate that R-q
and R-s selectively couple to Gq/11 and Gs, respectively. Importantly,
ACh had virtually no activity at R-q and R-s in any of the second
messenger assays used (SI Appendix, Figs. S1 C, D, G, H and S2).
SI Appendix, Fig. S1 I and J shows that CNO-mediated activation
of R-q and R-s was characterized by high efficacy (Emax values), as
compared with other Gq/11- or Gs-coupled receptors, respectively.
Whereas R-q was devoid of agonist-independent (basal) signaling
(Fig. S1I), R-s displayed a small degree of constitutive activity (SI
Appendix, Fig. S1J).
Generation of Mutant Mice Expressing R-q and R-s in Pancreatic  Cells.
Using standard transgenic techniques, we next generated mutant
mice that specifically expressed R-q or R-s only in pancreatic  cells
only (see Materials and Methods for details). We then selected two
mouse lines that expressed similar numbers of R-q and R-s in their
pancreatic islets for detailed phenotyping studies (number of [3H]-
NMS binding sites in fmol/mg membrane protein: R-q, 412  109;
R-s, 475  35). These two mouse strains are hereafter referred to
as -R-q and -R-s Tg mice. RT-PCR studies confirmed that R-q
and R-s transcripts were not detectable in tissues other than
pancreatic islets (SI Appendix, Fig. S3). All mutant and WT control
mice used had a pure C57BL/6NTac background.
Initial Physiological Characterization of -R-q and -R-s Tg Mice. Initial
phenotyping studies showed that growth curves, blood glucose
levels, insulin sensitivity, and plasma insulin and glucagon levels
were not significantly different between -R-q Tg mice and their
control littermates (SI Appendix, Fig. S4), indicating that the R-q
receptor was devoid of ligand-independent signaling in vivo. A
similar pattern was observed with -R-s Tg mice, except that freely
fed -R-s Tg mice showed a significant decrease (by 20–25%) in
blood glucose levels (compared to WT control mice) (SI Appendix,
Fig. S4 D and F). This effect was not observed with fasted -R-s Tg
mice (SI Appendix, Fig. S4I).
The observation that freely fed -R-s Tg mice showed reduced
blood glucose levels may reflect the fact that the R-s receptor
retained some degree of constitutive activity in vivo, consistent with
the in vitro data (SI Appendix, Fig. S1J). Freely fed -R-s Tg mice
displayed normal plasma insulin levels (SI Appendix, Fig. S4G), and
the presence of the -R-s transgene had no effect on insulin
sensitivity (SI Appendix, Fig. S4E). One possibility therefore is that
constitutive signaling by R-s triggered increased insulin release in
-R-s Tg mice during times of feeding, resulting in reduced blood
glucose levels. Whereas the increase in plasma insulin levels may be
transient, effects on blood glucose levels may still persist even after
insulin levels have returned to normal levels.
CNO Administration to -R-q and -R-s Tg Mice Induces Profound
Dose-Dependent Hypoglycemic Effects. To determine the in vivo
effects of acute activation of either  cell Gq/11 or Gs signaling on
glucose homeostasis, we injected -R-q and -R-s Tg mice with
increasing doses of CNO (0.0001–10 mg/kg i.p.) and monitored
blood glucose levels for a 2-h period. All mice had free access to
food until the beginning of the experiment and were kept fasting
after CNO (or saline) administration. In both -R-q and -R-s Tg
mice, CNO treatment resulted in a dose-dependent decrease in
blood glucose levels (Fig. 2 A and B) and increased plasma insulin
concentrations (SI Appendix, Fig. S5), demonstrating that the
degree of  cell G protein signaling could be titrated according to
the CNO dose administered. In general, the CNO-induced hypo-
glycemic and insulin-releasing effects were more pronounced in
-R-q than in -R-s Tg mice.
To determine the duration of the CNO-induced hypoglycemic
responses, freely fed -R-q and -R-s Tg mice were injected with
CNO (1 mg/kg i.p.), and blood glucose levels were monitored over
a 24-h period. Blood glucose levels were lowest at the 2 h time point
and remained significantly reduced compared to preinjection values
for at least 8 h in both mutant mouse lines (Fig. 2C).
To examine whether CNO was back-transformed into the parent
drug, clozapine, we injected WT mice (C57BL/6NTac mice) with
CNO (1 mg/kg i.p.) and collected blood samples for the measure-
ment of CNO and clozapine plasma concentrations over a 2-h
period. This analysis showed that no significant back-transforma-
tion of CNO to clozapine occurred during the entire observation
period (SI Appendix, Fig. S6).
Fig. 1. Schematic representation of the structures of the R-q and R-s designer
receptors. The Y148C and A238G point mutations (rat M3R sequence) were
introduced intothethirdandfifthtransmembranedomainsof thetworeceptors.
These two point mutations prevent the binding of ACh, the endogenous M3R
ligand (11). However, both R-q and R-s can be activated by CNO, an otherwise
pharmacologically inert compound, with high potency and efficacy. Functional
studies showed that CNO binding to R-q and R-s leads to the selective activation
of Gq/11 and Gs, respectively (see text for details). Note that the Y148C and A238G
point mutations (rat M3R sequence) correspond to the Y149C and A239G point
mutations in the human M3R (11).
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Acute Activation of Gq/11 and Gs in  Cells Results in Marked Improve-
ments in Glucose Tolerance Due to Greatly Enhanced Insulin Release. To
assess the effects of acute activation of  cell Gq/11 or Gs signaling
on glucose tolerance, we carried out i.p. glucose tolerance tests
(IGTT) with -R-q and -R-s Tg mice, respectively. In both
transgenic mouse lines, co-injection of CNO (1 mg/kg i.p.) with
glucose (2 g/kg i.p.) resulted in a pronounced improvement in
glucose tolerance (Fig. 3 A and D). In the case of -R-q Tg mice,
the CNO effect was so dramatic that no increases in blood glucose
levels were observed at all at any of the indicated time points (Fig.
3A). In fact, CNO-treated -R-q Tg mice became profoundly
hypoglycemic at the 1 and 2 h time points (Fig. 3A).
To test the hypothesis that the CNO-induced improvements in
glucose tolerance displayed by the -R-q and -R-s Tg mice were
due to enhanced insulin release, we monitored changes in plasma
insulin levels following co-injection of CNO (1 mg/kg i.p.) with
glucose (2 g/kg i.p). Strikingly, co-injected -R-q and -R-s Tg mice
showed pronounced increases in in vivo insulin release, as com-
pared to transgenic mice that had received glucose alone (Fig. 3 B
and E). Co-injected -R-q Tg mice released approximately seven
times more insulin over the 2-h observation period than -R-q Tg
mice injected solely with glucose (Fig. 3C). In contrast, co-injected
-R-s Tg mice released only approximately 2.5 times more insulin
than -R-s Tg mice that had received only glucose (Fig. 3F),
consistent with the results of the glucose tolerance tests.
-R-q and -R-s Tg mice injected with glucose alone showed
Fig. 2. Effect of CNO on blood glucose levels in -R-q and -R-s Tg mice. (A and B) Hypoglycemic effects following CNO administration in -R-q and -R-s Tg mice.
-R-q Tg (A) and -R-s Tg mice (B) received a single i.p injection of increasing doses of CNO or vehicle (saline), and blood glucose levels were measured at the indicated
time points. (C) Time course of the hypoglycemic effects of CNO. -R-q and -R-s Tg mice received a single dose of CNO (1 mg/kg i.p.), and blood glucose levels were
monitored over a 24-h period. WT mice that had received either saline or the same dose of CNO served as controls. The data obtained with the two WT groups were
pooled for the sake of clarity (no significant differences were found between these two groups). In all experiments, 3-month-old female mice with free access to food
were used (five to eight mice per dose and/or group). Data are presented as means  SEM.
Fig. 3. Effect of CNO on glucose tolerance and insulin secretion in -R-q and -R-s Tg mice. (A and D) i.p. glucose tolerance test in -R-q and -R-s Tg mice and control
littermates. Blood glucose levels were measured at the indicated time points following i.p. administration of glucose (2 g/kg). Glucose was injected either alone (-CNO)
or together with CNO (1 mg/kg i.p.). (B, C, E, and F) Plasma insulin levels in glucose-injected -R-q and -R-s Tg mice and control littermates. Plasma insulin levels were
measured at the indicated time points following i.p. administration of glucose (2 g/kg). Glucose was injected either alone (-CNO) or together with CNO (1 mg/kg i.p).
In panels C and F, total insulin secretion from 0–120 min is expressed as area under the curve (AUC). (G–J) First-phase insulin release in glucose-injected -R-q and -R-s
Tg mice and control littermates. Plasma insulin levels were measured immediately before (time 0) and 2, 5, 10, and 15 min after glucose administration (3 g/kg i.p.).
Glucose was injected either alone or together with CNO (1 mg/kg i.p). In panels H and J, first-phase insulin release from 0–10 min is expressed as AUC. All experiments
were carried out with 2- to 3-month-old female mice (five to seven mice per group). Data are presented as means  SEM. *, P  0.05; **, P  0.005; ***, P  0.0005,
as compared to the corresponding non-CNO-treated Tg mouse group.







blood glucose and insulin excursions similar to the corresponding
WT mice (Fig. 3 A, B, D, and E), indicating that basal (CNO-
independent) signaling by R-s (SI Appendix, Fig. S1J) did not
confound the outcome of the glucose tolerance and in vivo insulin
release studies.
Given the importance of acute (first-phase) insulin release for
proper glucose homeostasis (13, 14), we carried out additional in
vivo insulin release experiments examining increases in plasma
insulin levels in -R-q and -R-s Tg mice 2, 5, 10, and 15 min after
glucose administration (3 g/kg i.p.). In these experiments, co-
injection of CNO (1 mg/kg i.p.) with glucose led to a dramatic
increase in in vivo insulin release at 2 min and all subsequent time
points (Fig. 3 G and I). Co-injected -R-q Tg mice released
approximately 12 times more insulin over the first 10 min following
CNO/glucose administration than -R-q Tg mice injected with
glucose alone (Fig. 3H). In contrast, co-injected -R-s Tg mice
released only approximately five times more insulin during this
period than -R-s Tg mice treated solely with glucose (Fig. 3J).
To examine the effects of CNO on first- and second-phase insulin
secretion in more detail, we carried out in vitro insulin release
studies using perifused islets prepared from -R-q and -R-s Tg
mice. We found that CNO treatment (0.1 M) of both -R-q and
-R-s islets significantly enhanced both first- and second-phase
insulin release in the presence of a high glucose concentration (16.7
mM) (SI Appendix, Figs. S7 and S8). In -R-q islets, we noted a
trend toward CNO-dependent increases in insulin secretion even at
a low glucose concentration (2.8 mM). However, this effect was not
consistently observed in all experiments (see legend to SI Appendix,
Fig. S7). To further examine the effect of CNO on insulin release
in -R-q islets at a low ambient glucose concentration, we carried
out additional insulin secretion studies using a static islet incubation
assay. Under these experimental conditions, CNO (0.1 M) had no
significant effect on insulin release at 3.3 mM glucose, but triggered
a profound increase in insulin secretion at 16.7 mM glucose, as
expected (SI Appendix, Fig. S9). These data indicate that CNO does
not consistently stimulate insulin release at low glucose concentra-
tions in islets prepared from -R-q mice.
The amount of insulin contained in pancreatic islets prepared
from -R-q and -R-s Tg mice and WT control littermates (2-
month-old females) did not differ significantly from each other
(insulin content in ng/g islet protein: WT, 29.1  1.9; -R-q,
40.3  8.1; -R-s, 44.5  5.5; means  SEM; three independent
batches of islets from different groups of mice were tested per
strain; P  0.05). However, there was a clear trend toward an
increase in islet insulin content in -R-s Tg mice.
Studies with Obese, Insulin-Resistant -R-q and -R-s Tg Mice. An
energy-rich, high-fat diet is known to trigger a number of metabolic
changes including impaired glucose tolerance and insulin resis-
tance. To examine to what extent acute activation of  cell Gq/11 or
Gs signaling affected the severity of these metabolic disturbances,
-R-q and -R-s Tg mice and their WT control littermates were fed
a high-fat diet (HFD; fat content: 35.5%, wt/wt) and then moni-
tored for a 12-week period. Expectedly, the transgenic mice and
their WT control littermates maintained on the HFD gained
significantly more weight than mice maintained on regular chow
(RC) (SI Appendix, Fig. S10 A and C). This HFD-associated weight
gain was accompanied by an approximately 3- to 5-fold increase in
plasma insulin levels, as compared to mice maintained on RC (SI
Appendix, Fig. S10 B and D), and greatly reduced insulin sensitivity,
as shown in insulin tolerance tests (SI Appendix, Fig. S10E),
indicative of an insulin-resistant state. Glucose tolerance tests (2 g
glucose/kg i.p.) demonstrated that the HFD triggered glucose
intolerance in WT and -R-q Tg mice (SI Appendix, Fig. S10F).
Strikingly, -R-q Tg mice that had received CNO (1 mg/kg i.p.),
together with the i.p glucose load, showed a dramatic improvement
in glucose tolerance (SI Appendix, Fig. S10F), accompanied by a
pronounced increase in in vivo insulin release (SI Appendix, Fig.
S10G), as compared to -R-q Tg mice treated with glucose alone.
Co-injected -R-q Tg mice exhibited an approximately 18-fold
increase in total insulin release during the 2-h observation period,
as compared with -R-q Tg mice that had received only glucose (SI
Appendix, Fig. S10H).
CNO (1 mg/kg i.p.) treatment of HFD -R-s Tg mice led to
qualitatively similar effects as described above for HFD -R-q Tg
mice (SI Appendix, Fig. S10 I–K). However, the CNO-dependent
effects on glucose tolerance and in vivo insulin release were clearly
less pronounced in HFD -R-s Tg mice.
Morphometric Analysis of Pancreata from -R-q and -R-s Tg Mice. To
examine the effect of chronic activation of either  cell Gq/11 or Gs
signaling on  cell mass, mean islet size, and islet density, -R-q and
-R-s Tg mice and WT control mice received daily injections of
CNO (1 mg/kg i.p.) or saline (controls) for a 2-week period. Total
pancreatic weights did not differ significantly among all groups
studied (Fig. 4A).
In WT mice, CNO treatment had no significant effect on  cell
mass, mean islet size, or islet density (Fig. 4 B–D). In contrast,
CNO-treated -R-q Tg mice showed an approximately 75% in-
crease in  cell mass, as compared to saline-treated -R-q Tg mice
(saline, 0.8 mg  0.1 mg; CNO, 1.4  0.1 mg; P  0.001; Fig. 4B).
This increase in  cell mass was accompanied by an approximately
60% increase in mean islet size in CNO-treated versus saline-
treated -R-q Tg mice (saline, 4,100  400 m2; CNO, 6,600  300
m2; P  0.001; Fig. 4C). Islet density was similar in saline-treated
and CNO-treated -R-q Tg mice (Fig. 4D), suggesting that en-
largement of existing islets is chiefly responsible for the increase in
 cell mass observed with CNO-treated -R-q Tg mice.
In contrast to saline-treated -R-q Tg mice, saline-treated -R-s
Tg mice showed an approximately 160% increase in  cell mass, as
compared to saline-treated WT mice (WT, 0.8  0.1 mg; -R-s,
2.1  0.3 mg; P  0.0001; Fig. 4B), consistent with the concept that
basal R-s signaling triggers an increase in  cell mass. CNO
treatment of -R-s Tg mice did not lead to an additional increase
in  cell mass (Fig. 4B). Unlike CNO-treated -R-q Tg mice, both
saline- and CNO-treated -R-s Tg mice showed no significant
changes in mean islet size, as compared to the corresponding WT
control groups (Fig. 4C). However, in contrast to saline-treated
-R-q Tg mice, saline-treated -R-s Tg mice exhibited an approx-
imately 2-fold increase in islet density, as compared to saline-
treated WT mice (WT, 1.2  0.3 islets/mm2; -R-s, 2.5  0.9
islets/mm2; P  0.0001; Fig. 4D). CNO-treated -R-s Tg mice
exhibited a similar increase in islet density, as compared to saline-
treated or CNO-treated WT control mice (Fig. 4D), indicating that
an increase in islet density is primarily responsible for the increase
in  cell mass observed with -R-s Tg mice. Representative images
of pancreatic sections stained with an anti-insulin antibody are
shown in SI Appendix, Fig. S11.
CNO treatment had no significant effect on the number of
TUNEL-positive islet cells (a measure of cell apoptosis) in any of
the mouse strains studied. However, CNO caused a significant
increase in  cell (islet cell) size (by 15–30%) in both -R-q Tg
and -R-s Tg mice (Fig. 4E). Taken together, these data suggest
that the increase in  cell mass observed following  cell Gq/11 or
Gs activation involves  cell hypertrophy and, possibly, an enhanced
rate of  cell proliferation.
Islet Gene Expression Analysis. We next used real-time qRT-PCR to
examine the effects of conditional  cell Gq/11 or Gs activation on
the transcription of several genes important for  cell function and
growth. To minimize the confounding effects of altered blood
glucose levels on  cell (islet) gene expression (15), we carried out
gene expression studies with freshly isolated islets cultured in the
presence of a constant (physiological) concentration of glucose (5.5
mM). Islets were prepared from -R-q and -R-s Tg mice and WT
control littermates and then treated with CNO (1 M) at 37 °C for
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3 h or left untreated (controls). Subsequently, total RNA was
isolated and subjected to real-time qRT-PCR using validated
primers. SI Appendix, Fig. S12 shows that CNO treatment of -R-q
Tg islets led to a small but significant increase in insulin (Ins2) and
proprotein convertase 1 and 2 transcript levels (P  0.05). A similar
trend was also observed with CNO-treated -R-s Tg islets. Most
remarkably, CNO treatment of -R-q Tg islets resulted in a
pronounced (6-fold) increase in the levels of IRS-2 mRNA (P 
0.0005; SI Appendix, Fig. S12). A similar but quantitatively smaller
increase in IRS-2 gene expression (2-fold) was also seen with
CNO-treated -R-s Tg islets (P  0.05).
We also noted several pathway-specific changes in gene expres-
sion. Whereas CNO treatment of -R-q Tg islets led to significantly
reduced expression levels of Glut-2 and pyruvate carboxylase, no
changes in the expression levels of these genes were observed with
CNO-treated -R-s Tg islets (SI Appendix, Fig. S12). On the other
hand, CNO-treated -R-s Tg islets showed a robust increase
(4-fold) in acetyl-CoA carboxylase-2 (ACC2) gene expression
levels, an effect that was not seen with CNO-treated -R-q Tg islets
(SI Appendix, Fig. S12).
We also examined the mRNA expression levels of several
transcription factors and various other genes known to be important
for  cell development and growth, including Pdx1, Neurog3,
Nkx6–1, Neurod1, Mafa, Hnf4a, Ccnd1 (cyclin D1), Ccnd2 (cyclin
D2), Cdk4, and Myc. However, under our experimental conditions,
CNO treatment of -R-q or -R-s Tg islets failed to stimulate the
expression of any of these genes.
Discussion
In this study, we used a chemical-genetic strategy to explore the
in vivo consequences of selective and conditional activation of 
cell Gq/11 or Gs signaling. Whereas the data obtained with the
-R-s Tg mice largely confirm previous results (5–7), the phe-
notypic analysis of -R-q Tg mice has led to several important
insights into the in vivo consequences of conditional and selec-
tive activation of  cell Gq/11 signaling. Moreover, since the R-q
receptor, in contrast to the R-s construct, lacked ligand-
independent signaling, the phenotypes displayed by the -R-q Tg
mice can be interpreted in a more straightforward fashion.
Significantly, we demonstrated that selective activation of  cell
Gq/11 signaling in vivo triggered a pronounced increase in
first-phase insulin release, in addition to a long-lasting second
phase of insulin release. This observation is of particular clinical
relevance, since first-phase insulin release is considered critical
for postprandial glucose homeostasis, and a reduction or loss of
this response is a characteristic marker of  cell dysfunction in
the early stages of type 2 diabetes (13, 14). Importantly, condi-
tional and selective activation of  cell Gq/11 signaling in vivo also
led to a striking improvement in glucose tolerance not only in
mice consuming RC but also in obese, insulin-resistant mice.
We also made the observation that chronic, selective activation
of  cell Gq/11 signaling resulted in a significant elevation in  cell
mass, associated with an increase in mean islet size and  cell
hypertrophy. Gene expression analysis demonstrated that condi-
tional activation of  cell Gq/11 signaling triggered a robust increase
in IRS-2 mRNA expression, probably due to Gq/11-mediated in-
creases in intracellular Ca2 levels (8, 16). Given the key role of
IRS-2 in maintaining  cell function and mass (17, 18), it is likely
that the observed increase in IRS-2 expression plays a major role
in mediating the observed Gq/11-dependent increase in  cell mass.
Clearly, more detailed mechanistic studies are needed to delineate
the molecular pathways that link Gq/11 activation to increased IRS-2
expression and  cell mass. Gene expression analysis also showed
that conditional activation of  cell Gq/11 signaling resulted in small
but significant increases in insulin (Ins2) and proprotein convertase
1 and 2 transcript levels, suggesting that  cell Gq/11 signaling exerts
a stimulatory effect on insulin synthesis.
The results obtained with the -R-s Tg mice are largely consistent
with previous studies suggesting that activation of  cell Gs improves
 cell function, including an increase in  cell mass (5–7), thus
representing a promising strategy to reduce pathologically elevated
blood glucose levels. Consistent with this notion, exendin 4, which
acts as an agonist at the Gs-coupled GLP-1 receptor, has been
approved for the treatment of type 2 diabetes recently (5–7).
In general, the Gq/11-mediated in vivo metabolic effects were
more pronounced than the corresponding Gs responses. However,
a direct comparison between the effects observed with the two
different mutant mouse strains is complicated by the fact that R-s
showed some degree of agonist-independent signaling that may
have triggered counter-regulatory responses in the -R-s Tg mice.
In agreement with this notion, Ma et al. (19) demonstrated that the
expression of a constitutively active version of Gs in  cells of
Fig. 4. Morphometric analysis of pancreata from -R-q and -R-s Tg mice and control littermates. -R-q and -R-s Tg mice and control littermates were treated for
2 weeks with daily injections of CNO (1 mg/kg i.p.) or saline (controls). (A) Total pancreatic weight (in mg). (B)  Cell mass (in mg). (C) Mean islet size (in m2). (D) Islet
density (expressed as number of islets/mm2 islet area). (E)  Cell (islet cell) size (in m2). All experiments were carried out with 2-month-old female mice (three to six
mice per group; for details, see Materials and Methods). The data obtained with the two WT groups were pooled for the sake of clarity (no significant differences were
found between these two groups). Data are presented as means  SEM. *, P  0.05, **, P  0.005, ***, P  0.0005.







transgenic mice resulted in complex counter-regulatory effects. It is
therefore conceivable that similar processes have occurred in -R-s
Tg mice, making a proper comparison between the in vivo pheno-
types of the -R-q and -R-s Tg mice impossible. However,
independent of these considerations, the robust, CNO-dependent
in vivo phenotypes displayed by the -R-q Tg mice strongly suggest
that drugs that can enhance signaling through  cell Gq/11-coupled
receptors may prove useful in the treatment of type 2 diabetes and
glucose intolerance, similar to GLP-1 receptor agonists (5–7).
The use of engineered GPCRs with modified ligand binding
properties to study various aspects of GPCR biology has been
pioneered by Conklin and coworkers (20). However, in contrast to
previous studies, the present in vivo study uses engineered GPCRs
that are unable to bind endogenous ligand but can be efficiently
activated by an otherwise pharmacologically inert drug.
In conclusion, the chemical-genetic approach described here has
led to important insights into the functional roles of distinct G
protein pathways in regulating  cell function in vivo. In principal,
this technology can be applied to study the physiological and
pathophysiological relevance of distinct G protein signaling path-
ways in virtually every cell type.
Materials and Methods
Drugs and WT Receptor Expression Constructs. Clozapine-N-oxide (CNO) was
purchased from Biomol International. All other drugs were from Sigma-Aldrich.
[3H]N-methylscopolamine ([3H]-NMS) and myo-[3H] inositol were obtained from
Perkin-Elmer Life and Analytical Sciences.
The mouse M3R coding sequence was cut out from a segment of cloned
genomic DNA (21) and inserted into the pcD-PS mammalian expression vector.
Themammalianexpressionvectors codingfor thehumanV2 vasopressin receptor
(hV2-pcD-PS) (22) and the turkey 1-adrenergic receptor have been described
previously (1-pCMV) (23).
Generation of CNO-Sensitive Mutant M3Rs with Distinct G Protein Coupling Profiles.
Mammalian expression plasmids coding for the R-q and R-s designer receptors
(Fig. 1) were generated by standard molecular biological techniques (for details,
see SI Appendix).
Transient Expression of Receptors in COS-7 Cells. COS-7 cells were grown as
monolayers as described (24). For transfections, cells were plated at a density of
1  106 cells per 10-cm dish. About 24 h later, cells were transfected with 2 g
plasmid DNA using the Lipofectamine plus kit (Invitrogen).
[3H]-NMS Radioligand Binding Assays. [3H]-NMS saturation and inhibition binding
assays were performed using membranes prepared from transfected COS-7 cells
as described previously (24). ACh and CNO IC50 values were converted to Ki values
using the Cheng-Prusoff equation.
Inositol Phosphate and cAMP Assays. Approximately 24 h after transfection,
receptor-expressing COS-7 cells were placed into 6-well plates at a density of 1 
106 cells/well. Cells were then incubated at 37 °C for 24 h with 1 Ci/mL myo-
[3H]inositol. Receptor-mediated increases in intracellular [3H]-IP1 levels were then
determined as described (24). In a similar fashion, receptor-mediated increases in
intracellular cAMP assays were measured via ELISA according to the manufactur-
er’s protocol (cAMP; Biotrak; Amersham Biosciences).
Generation of Transgenic Mice and Mouse Maintenance and Diet. Mutant mice
selectively expressing the R-q and R-s mutant receptors in their pancreatic  cells
were obtained by using standard transgenic techniques (for details, see SI Ap-
pendix). All mouse lines were maintained on a pure C57BL/6NTac background.
Mouse genotyping and RT-PCR analysis of transgene expression were carried out
as described under SI Appendix.
Unless noted otherwise, 2- to 4-month-old female or male mice were used for
phenotypingstudies.Micewere fedad libitumandkeptona12-h light,12-hdark
cycle. For diet-induced obesity studies, mice were fed a diet containing 35.5%
calories from fat (product no. F3282; BioServ). All experiments were approved by
the Animal Care and Use Committee of the National Institute of Diabetes and
Digestive and Kidney Diseases, NIH, Bethesda, MD.
Physiological Studies. Glucose and insulin tolerance tests were carried out after an
overnight fast (10–12 h), and plasma insulin and glucagon levels were deter-
mined via ELISA, as described in detail previously (9).
Islet Binding Assays and Determination of Islet Insulin Content. R-q and R-s
expressionlevels inmembranepreparationspreparedfromisolatedisletsof-R-q
and -R-s Tg mice were quantitated in radioligand binding studies as described
previously (9), using a saturating concentration of [3H]-NMS (20 nM; three to four
mice per strain per experiment). Islet insulin content was measured by using an
acid-ethanol method, as described previously (9). For each mouse strain, three to
four separate batches of islets (30 islets per batch) were prepared from three to
four different mice.
Morphometric Analysis of Pancreatic Islets. Islet morphometric studies were
performed with 8-week-old female mice (three mice per strain and treatment
group) by using standard techniques (for details, see SI Appendix).
Real-Time qRT-PCR Analysis of Islet Gene Expression. Total RNA was prepared from
pancreatic islets of -R-q and -R-s Tg mice and WT littermates (three to four mice
per strain per experiment). Subsequently, gene expression levels were deter-
mined via real-time qRT-PCR (for details, see SI Appendix).
Statistics. Data are expressed as means  SEM or SD for the indicated number of
observations.Forcomparisonsbetweentwogroups, theunpairedStudent’s t-test
(two-tailed)wasused.Formultiple comparisons, theone-wayanalysisofvariance
(ANOVA) was used. A P value of 0.05 was considered statistically significant.
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